# Cilengitide in Treating Patients With Acute Myeloid Leukemia

> **NCT00089388** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- Adult Acute Basophilic Leukemia
- Adult Acute Eosinophilic Leukemia
- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Erythroleukemia (M6a)
- Adult Pure Erythroid Leukemia (M6b)

## Interventions

- **DRUG:** cilengitide

## Key facts

- **NCT ID:** NCT00089388
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089388, "Cilengitide in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00089388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*